KeyBanc initiated coverage of AptarGroup (ATR) with an Overweight rating and $220 price target The firm believes the company’s position as a leader in inhalable drug delivery systems and its growing position in advanced delivery technologies are not reflected in the share price. AptarGroup has been transitioning from a diversified packaging company to a more concentrated healthcare business, the analyst tells investors in a research note. KeyBanc believes the company’s revenue growth will accelerate and margins expand as it continues the transition.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup: Strong Performance and Growth Potential Amid Temporary Challenges
- AptarGroup price target lowered to $172 from $182 at Raymond James
- AptarGroup price target lowered to $153 from $173 at Wells Fargo
- AptarGroup Reports Strong Q2 2025 Results
- AptarGroup Earnings Call: Pharma and Closures Shine